Emerging Infectious Disease Information
Candida auris is an emerging, multidrug-resistant yeast causing invasive infections with high mortality. It has a high potential to cause outbreaks in healthcare facilities.
ARUP offers fungal culture, yeast identification by ITS rDNA sequencing, and susceptibility testing to identify this organism. ARUP will forward identified isolates to the CDC.
The following tests are available:
- Fungal Culture (ARUP test code 0060149)
- Fungal (Mold/Yeast) Identification (ARUP test code 0060163)
- Fungal Identification by ITS rDNA Sequencing (ARUP test code 0060756)
- Antimicrobial Susceptibility—Fungal, Yeasts and Molds (ARUP test code 2009257)
Zika Virus Testing
ARUP Laboratories now offers IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) detection for Zika virus infections.
Per CDC guidelines, ARUP does not perform viral cultures on samples from patients suspected to have MERS-CoV. We offer the following PCR assays and can assist with ruling out other respiratory pathogens: Respiratory Viral Panel (2007805), Chlamydia pneumonia (0060715), Legionella Species (2010125), and Mycoplasma pneumoniae (0060256).More information about MERS-CoV testing can be found on the CDC website.